King’s College London’s multiomics research will be powered by SZAOMICS

SZAOMICS has entered into a multi-year collaborative agreement with King’s College London to provide multi-omics services in support of drug development and related research efforts.

SZAOMICS will leverage its proprietary platform to analyze a range of biological samples to accelerate research, drug development, and precision medicine. “SZAOMICS is proud to contribute to research to help accelerate important discoveries that could improve human health,” says Prof. Ahmet Tarik Baykal, General Manager, SZAOMICS. “Multi-omics is an essential element of the scientific approach that is being employed by King’s College London to transform healthcare by understanding disease progression and therapeutic response more deeply.” Through this collaboration, SZAOMICS will perform multi-omics analysis and provide a biological interpretation of results for large-scale population health initiatives, with the goal of accelerating King’s College London research and drug development initiatives